Genetic Mutations Affecting Response to Drugs Are Common in Veterans

Genetic Mutations Affecting Response to Drugs Are Common in Veterans

SALT LAKE CITY — A massive VA study revealed that 99% of veterans have at least one genetic mutation known to affect response to specific drugs, including some commonly prescribed antidepressants, anticoagulants, antivirals, oncology medications and statins. That raises the question of who should be tested for which variants and when, which has stirred lively debate within the VA.

Combat PTSD/TBI Increases Amygdala Size in Military Patients

SAN DIEGO — The region of the brain that processes fear, anxiety, aggression and similar emotions is larger in veterans and active-duty service members with combat-related post-traumatic stress disorder and mild traumatic brain injury than those with brain injuries only.

VA Expands Parkinson’s Disease Services to Improve Patient Care

PHILADELPHIA—Building on the success of the Parkinson’s Disease Research, Education and Clinical Centers, established in 2001, the VA has expanded care for the nearly 100,000 veterans affected by the neurodegenerative disease through the creation of the National VA Parkinson’s Disease Consortium.

Benzodiazepines Prescribed Long-Term for COPD/PTSD

SEATTLE — Symptoms of insomnia and anxiety are common among patients with chronic obstructive pulmonary disease, and that is especially the case among patients with comorbid mental health disorders such as posttraumatic stress disorder, according to a new study.

MHS Pharmacies Prescribed 6,200 Naloxone Kits Under New Directive

MHS Pharmacies Prescribed 6,200 Naloxone Kits Under New Directive

FALLS CHURCH, VA — In June 2018, Defense Health Agency Director Raquel Bono, MD, directed all MHS pharmacies to dispense the opioid reversal agent naloxone to eligible beneficiaries and those who request it without requiring a prescription. Since then, MHS pharmacists have provided more than 6,200 kits.

Debate Continues on Esketamine Efficacy and Safety for Depression Treatment

Debate Continues on Esketamine Efficacy and Safety for Depression Treatment

PHILADELPHIA—Is esketamine a revolutionary treatment for depression or just another moderately effective adjunctive medication with some potentially serious risks? The VA’s Medical Advisory Panel leaned toward the latter position when it decided in June to approve the use of esketamine on a nonformulary basis for individuals who have previously failed at least two trials of other antidepressants.

VA Researcher Helps Develop Promising New Pain Drug

NEW ORLEANS—A new drug with less risk for addiction and overdose compared to currently available opioid medications is showing promise, according to a recently published research article. The drug, developed at Southeast Louisiana Veterans Health Care System and...

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose was to summarize recent...